Jane Street Group LLC Sells 14,288 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA)

Jane Street Group LLC lowered its stake in Akoya Biosciences, Inc. (NASDAQ:AKYA) by 32.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,421 shares of the company’s stock after selling 14,288 shares during the quarter. Jane Street Group LLC’s holdings in Akoya Biosciences were worth $83,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Regal Investment Advisors LLC increased its holdings in shares of Akoya Biosciences by 64.3% in the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock worth $44,000 after purchasing an additional 7,340 shares during the period. Bank of New York Mellon Corp grew its position in Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after buying an additional 9,429 shares in the last quarter. GSA Capital Partners LLP increased its stake in Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after acquiring an additional 144,903 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Akoya Biosciences by 4.2% in the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after acquiring an additional 18,361 shares in the last quarter. Institutional investors own 79.42% of the company’s stock.

Akoya Biosciences Stock Performance

Shares of AKYA stock opened at $2.75 on Thursday. The firm has a market capitalization of $136.30 million, a price-to-earnings ratio of -2.33 and a beta of 1.18. The stock has a fifty day moving average of $2.48 and a 200 day moving average of $2.54. Akoya Biosciences, Inc. has a 52 week low of $1.88 and a 52 week high of $6.31. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on AKYA shares. Canaccord Genuity Group downgraded shares of Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday. Craig Hallum lowered shares of Akoya Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $7.00 to $5.00 in a report on Friday, November 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of Akoya Biosciences in a report on Tuesday, November 19th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Akoya Biosciences currently has a consensus rating of “Hold” and an average target price of $5.43.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.